@entity6237 is a class Ic antiarrhythmic agent that has an important role as part of rhythm control strategies in @entity1 with @entity955 ( @entity955 ). Early clinical data on the use of @entity6237 showed an increase in @entity943 and mortality compared with placebo in @entity1 with a previous @entity583 and asymptomatic or mildly symptomatic @entity943 . These findings only apply to a specific group of @entity1 with @entity1002 and @entity299 , but had a negative impact on the use of class Ic antiarrhythmics across all indications and @entity1 groups. The aim of this review was to evaluate the available safety data for @entity6237 in the literature and to assess its current use in @entity1 with @entity955 . Current European guidelines now recommend the use of @entity6237 in carefully selected groups of @entity1 with @entity955 who do not have structural @entity299 . This includes for the cardioversion of recent-onset @entity955 , pretreatment prior to direct current cardioversion, out-of-hospital acute oral therapy ('pill-in-the-pocket' approach) and for the ongoing maintenance of sinus rhythm. Potential cardiac adverse effects of @entity6237 include proarrhythmia, @entity616 and negative inotropic effects. @entity1296 is the most frequent non-cardiac side effect, followed by blurred vision and difficulty focusing; these are almost all mild, transient and tolerable. Data from recent clinical trials in @entity1 with @entity943 suggest that @entity6237 has a good tolerability profile in groups of appropriately selected @entity1 . Caution is required when using @entity6237 in @entity1 with @entity8 , and there are a number of drug interactions, but these are well documented and manageable. Overall, @entity6237 is a good choice for the pharmacological management of @entity955 . It has a good safety record and low incidence of adverse effects, rare end-organ @entity137 and a low risk of @entity67 . To ensure that the benefits of treatment outweigh any potential risks, careful @entity1 selection and monitoring is required.

Safety of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['Dizziness'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity616 :: ('MESH:D006327', 'Disease') :: ['conduction abnormalities'] @entity6237 :: ('MESH:D005424', 'Chemical') :: ['flecainide', 'Flecainide'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF'] @entity299 :: ('MESH:D006331', 'Disease') :: ['ischaemic heart disease', 'heart disease'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular proarrhythmia'] @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmias', 'supraventricular arrhythmias', 'arrhythmias'] @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular dysfunction']
@entity6237 :: (MESH:D005424,Chemical) :: ['flecainide']
